Brigitte Boisselier Biography
She received her grant to pursue further studies abroad and landed in the US in 1982 where she was welcomed to the research team of a professor of the University of Houston, TX. Later she received her second Ph.D. in electrochemistry from the University of Houston in less than 3 years, a record time for that chemistry department.
Brigitte then chose to return to France in order to raise her children close to her family. She became Vice Director of Research and Development at Air Liquide, a multinational chemical company, managing research teams in France, USA and Japan. However her aspirations for more fundamental research were not satisfied, her interest for human chemistry and cellular communication kept growing. The cloning of the sheep Dolly in 1997 made headlines and was an example of what she had claimed was possible. Brigitte was compelled to take a public stand in support of science and fight against religious prejudice. Air Liquide didn’t agree with her public view in support of human cloning.
Brigitte then decided to launch her first company, Clonaid with the aim of cloning human beings despite the strong opposition from the establishment. During her search for funding, she taught chemistry at SUNY and biochemistry at Hamilton College in the state of New York. By the end of 2000, she had gathered the necessary funds and a competent scientific team able to prepare the embryos that would later become the first human clones born in December 2002 and early January 2003.
A whirlwind of interest and publicity followed which included appearance on most major media in the world as well as before the United States Congress and the US Academy of Sciences to present her view and expertise on human cloning.
After a few years touring the world and giving conferences on the benefits of human cloning, she extended her activities into the production of embryonic stem cells for rejuvenation purposes and co-funded Stemaid. In 2008, as part of a clinical trial, she was the first to receive an embryonic stem cell transplant.
Over the years that followed, Brigitte and her team have been refining protocols to help people who suffer from brain injuries as well as heart and kidney failures, as no therapy is available today to repair damaged organs.
She coordinated a first clinical trial on age reversal in 2011 that showed that regular injections of embryonic stem cells can increase the telomere length of the DNA and therefore increase one’s lifespan. With only 12 injections over the course of a year, the participants had their telomere length increased by an average of 14% which represents a remarkable advancement in age reversing.
In 2013, Stemaid partnered with A1Stem Cells to make the cells available to the public.
Brigitte is also an active member of the Raelian Movement and the President of Clitoraid, a non-profit organization that she launched in 2006, helping to surgically repair women who have been genitally mutilated.
She currently lives in the USA. Her passion remains in reversing the aging process. She is now conducting a new clinical trial involving stem cells in combination with energetic tools, studying their impact on age reversal at the epigenetic level.